Chromadex Corp Stock Today
| CDXC Stock | USD 7.59 0.13 1.74% |
Performance13 of 100
| Odds Of DistressLess than 33
|
Chromadex Corp is trading at 7.59 as of the 26th of November 2024, a 1.74% increase since the beginning of the trading day. The stock's open price was 7.46. Chromadex Corp has about a 33 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Chromadex Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of May 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of July 2008 | Category Consumer Defensive | Classification Health Care |
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. ChromaDex Corporation is headquartered in Los Angeles, California. Chromadex Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 76.38 M outstanding shares of which 2.6 M shares are currently shorted by private and institutional investors with about 9.98 trading days to cover. More on Chromadex Corp
Moving against Chromadex Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Chromadex Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Frank Jaksch | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Consumer Defensive, NASDAQ Composite, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsChromadex Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Chromadex Corp's financial leverage. It provides some insight into what part of Chromadex Corp's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chromadex Corp (CDXC) is traded on NASDAQ Exchange in USA. It is located in 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024 and employs 106 people. Chromadex Corp is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 569.82 M. Chromadex Corp conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 76.38 M outstanding shares of which 2.6 M shares are currently shorted by private and institutional investors with about 9.98 trading days to cover.
Chromadex Corp currently holds about 16.87 M in cash with 7.12 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25.
Check Chromadex Corp Probability Of Bankruptcy
Ownership AllocationChromadex Corp holds a total of 76.38 Million outstanding shares. Chromadex Corp retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Chromadex Ownership Details
Chromadex Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-06-30 | 192.3 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 190.4 K | |
| Winton Capital Group Ltd | 2024-09-30 | 178.1 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 158.1 K | |
| Gamco Investors, Inc. Et Al | 2024-09-30 | 143.2 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 140.2 K | |
| Ubs Group Ag | 2024-06-30 | 139.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 139.5 K | |
| Strs Ohio | 2024-09-30 | 104.1 K | |
| Vanguard Group Inc | 2024-09-30 | 3.4 M | |
| Blackrock Inc | 2024-06-30 | 3.1 M |
Chromadex Corp Historical Income Statement
Chromadex Stock Against Markets
Chromadex Corp Corporate Management
| Kendall Knysch | Head Partnerships | Profile | |
| Heather Blarcom | Senior Secretary | Profile | |
| Andrew Shao | Senior Affairs | Profile | |
| Chu Yan | Managing Pacific | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromadex Corp. If investors know Chromadex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromadex Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.02 | Revenue Per Share 1.215 | Quarterly Revenue Growth 0.312 | Return On Assets 0.0051 | Return On Equity 0.0482 |
The market value of Chromadex Corp is measured differently than its book value, which is the value of Chromadex that is recorded on the company's balance sheet. Investors also form their own opinion of Chromadex Corp's value that differs from its market value or its book value, called intrinsic value, which is Chromadex Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromadex Corp's market value can be influenced by many factors that don't directly affect Chromadex Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chromadex Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Chromadex Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromadex Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.